Sign Up
Stories
DBV Technologies Reveals 2023 Financials
Share
BW Energy's Operational Developments and...
Babcock & Wilcox Boosts Earnings Target
Biopharma Companies Announce Public Offe...
ADRs Index Climbs, Blockchain Surges
ADRs Slump: Grifols S.A. Declines 21.8%
Amgen's Weight-Loss Drugs Market Entranc...
Overview
API
DBV Technologies, a biopharmaceutical company, will unveil its full year 2023 financial results and business update during a conference call on March 7, 2024. Specializing in food allergy treatments, the company is actively conducting clinical trials for Viaskin Peanut. DBV Technologies is publicly traded on Euronext Paris and Nasdaq Stock Market.
Ask a question
How do ongoing clinical trials of Viaskin Peanut position DBV Technologies in the biopharmaceutical industry?
How might the financial results impact DBV Technologies' future research and development efforts?
What potential market response can be expected following the disclosure of the 2023 financial results?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage